Scarica l'app Stockscreener
11.04
1.34%
-0.15
Dopo l'orario di chiusura:
11.04
Precedente Chiudi:
$11.19
Aprire:
$11.21
Volume 24 ore:
707.55K
Relative Volume:
1.22
Capitalizzazione di mercato:
$465.88M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-2.359
EPS:
-4.68
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
-13.68%
1M Prestazione:
-13.28%
6M Prestazione:
-16.49%
1 anno Prestazione:
-11.40%
Intervallo 1D:
$10.62
$11.60
Intervallo di 1 settimana:
$10.62
$12.78
Portata 52W:
$10.60
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Nome
Urogen Pharma Ltd
Settore
Industria
Telefono
972 9 770 7601
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Confronta URGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| URGN | 11.04 | 465.88M | 82.71M | -102.24M | -76.57M | -4.68 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-02-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-27 | Iniziato | Berenberg | Buy |
| 2020-04-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-13 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | National Securities | Neutral |
| 2019-05-30 | Iniziato | JP Morgan | Neutral |
| 2019-05-29 | Iniziato | Goldman | Neutral |
| 2019-01-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-04-04 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-11-15 | Reiterato | Oppenheimer | Outperform |
| 2017-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mostra tutto
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load? - Simply Wall St
RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com
Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com
Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com
RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com
UroGen Pharma: Choice Based On Near-Term High-Value PDUFA - Seeking Alpha
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended Septemb - Defense World
UroGen Pharma Reports Q3 Results and Drug Progress - TipRanks
HC Wainwright Forecasts Stronger Earnings for UroGen Pharma - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Morgan Stanley's Strategic Acquisition of UroGen Pharma Shares - GuruFocus.com
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - BioSpace
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
UroGen Pharma Ltd (URGN) Q3 2024 Earnings: EPS of ($0.55) and Re - GuruFocus.com
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
UroGen's JELMYTO Sales Surge 20% to $25.2M as FDA Fast-Tracks UGN-102 Review | URGN Stock News - StockTitan
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire
(URGN) Investment Analysis - Stock Traders Daily
Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire
(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
UroGen started at buy by EF Hutton, RTGel technology cited - MSN
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance
FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India
When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register
URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com
UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News
UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com UK
UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat
Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology
UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian
UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
UroGen Pharma (NASDAQ:URGN) Upgraded to "Strong-Buy" by EF Hutton Acquisition Co. I - MarketBeat
EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa
EF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy Recommendation - MSN
UroGen Pharma Ltd [URGN] Chief Medical Officer makes an insider sale of 859 shares worth 11,236. - Knox Daily
Healthy Upside Potential: UroGen Pharma Ltd (URGN) - SETE News
UroGen Pharma announces executive changes By Investing.com - Investing.com South Africa
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
UroGen Pharma Announces Departure of CFO and Appointment of New CFO - MarketBeat
UroGen Appoints Chris Degnan as Chief Financial Officer - citybiz
Urogen Pharma Ltd Azioni (URGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):